Ruxoprubart

Business news, market intelligence, and global industry analysis.

The Latest

VA Tech Wabag (NSE: WABAG) wins order from CMWSSB for 45 MLD Chennai TTRO plant

Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway

Representative image of enterprise cloud cybersecurity infrastructure illustrating how Accenture plc and Google Cloud are strengthening cloud security defenses against AI-driven cyber threats and multi-cloud security risks.

How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure

Four-decade-first: Lok Sabha votes down no-confidence motion against Speaker Om Birla

Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?

NovelMed Therapeutics advances Ruxoprubart with Phase II PNH results and a subcutaneous trial. Discover how it could reshape the complement inhibitor market.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

March 12, 2026